New York Senate Bill S07668

New York 2025-2026 Regular Session

• Introduced: 4/28/25
• Refer: 4/28/25
• Refer: 1/7/26

Caption

Prohibits the knowing sale of xylazine above a certain weight to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

Summary

This bill would add a new section to the General Business Law regulating the sale of xylazine, a veterinary sedative and anesthetic used in animals such as horses and cattle. The measure applies only to transactions involving 50 grams or more per occurrence and would prohibit businesses operating in New York from knowingly selling, offering for sale, or delivering that amount of xylazine to individuals unless the purchaser provides proof that the drug is intended for institutional, veterinary, or scientific purposes. It would also bar sales of 50 grams or more to anyone under 21. The bill further requires covered businesses to keep sales records, proof of age, and proof of intended use from purchasers. Violations would be subject to civil penalties enforced by the Attorney General: up to $3,000 for a first violation and $6,500 for each subsequent violation. Penalty revenue would be deposited into the New York State Drug Treatment and Public Education Fund, and the law would take effect 90 days after enactment.

Impact

The bill would create a new commercial restriction in the General Business Law aimed at limiting bulk sales of xylazine and imposing recordkeeping obligations on businesses, including corporations, partnerships, LLCs, firms, and online platforms. It would give the Attorney General enforcement authority and establish a civil penalty structure for violations. The measure would affect sellers of xylazine and purchasers seeking the drug for legitimate institutional, veterinary, or scientific uses, while leaving ordinary small-scale or non-covered transactions outside the bill’s scope.

Sentiment

The available legislative history suggests generally favorable sentiment toward the bill: it was introduced, read twice, and reported favorably from the Senate Consumer Protection Committee before being ordered to third reading as amended. No committee transcript or recorded vote information is provided, so there is no evidence in the record supplied of organized opposition or debate. The bill’s framing indicates support for tighter controls on a substance associated with misuse and public health concerns.

Contention

The main policy tension is between restricting access to xylazine to curb misuse and preserving legitimate access for veterinary, institutional, and scientific purposes. Potential points of contention include the 50-gram threshold, the age-21 sales ban, and the burden of recordkeeping and proof-of-use requirements on businesses and online sellers. Another possible issue is enforcement, since the bill relies on Attorney General actions and civil penalties rather than criminal sanctions.